Pharvaris price target raised to $37 from $34 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Pharvaris (PHVS) to $37 from $34 and keeps an Overweight rating on the shares. The company continues to anticipate topline data from the pivotal Phase RAPIDe-3 trial of deucrictibant for the on-demand treatment of hereditary angioedema attacks in Q4, which represents a meaningful near-term catalyst, the analyst tells investors in a research note.